Home Cart Sign in  
Chemical Structure| 918515-16-9 Chemical Structure| 918515-16-9

Structure of 918515-16-9

Chemical Structure| 918515-16-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Szmigiel-Bakalarz, Ksenia ; Kłopotowska, Dagmara ; Wietrzyk, Joanna ; Malik, Magdalena ; Morzyk-Ociepa, Barbara ;

Abstract: This study investigates the structural, vibrational, and biological properties of novel palladium(II) and platinum(II) complexes with 5-chloro-7-azaindole-3-carbaldehyde (5ClL) and 4- chloro-7-azaindole-3-carbaldehyde (4ClL) ligands. Infrared and Raman spectroscopy, combined with DFT (ωB97X-D) calculations, provided valuable information about metal-ligand interactions, the cis or trans conformation of the aldehyde group in the ligands, and the presence of trans isomers in the metal complexes obtained in the solid state. In vitro tests were used to evaluate the antiproliferative activity of the novel complexes against several cancer cell lines, including ovarian cancer (A2780), cisplatin-resistant ovarian cancer (A2780cis), colon cancer (HT-29), and triple-negative breast cancer (MDA-MB-231), as well as normal mouse fibroblasts (BALB/3T3). The platinum complex, trans-[PtCl2(5ClL)2], exhibited superior activity against A2780cis (IC50 = 4.96 ± 0.49 µM) and MDA-MB-231 (IC50 = 4.83 ± 0.38 µM) compared to cisplatin, while the palladium complexes (trans-[PdCl2 (4ClL)2] and trans-[PdCl2(5ClL)2]) demonstrated enhanced selectivity with reduced toxicity to normal fibroblasts (IC50 = 11.29 ± 6.65 µM and 14.98 ± 5.59 µM, respectively).

Keywords: 4-chloro-7-azaindole-3-carbaldehyde ; 5-chloro-7-azaindole-3-carbaldehyde ; platinum(II) complexes ; palladium(II) complexes ; IR spectroscopy ; Raman spectroscopy ; DFT ; antiproliferative activity

Purchased from AmBeed: ;

Alternative Products

Product Details of [ 918515-16-9 ]

CAS No. :918515-16-9
Formula : C8H5ClN2O
M.W : 180.59
SMILES Code : O=CC1=CNC2=NC=CC(Cl)=C21
MDL No. :MFCD09880129
InChI Key :DYWWVLQMUUZZRJ-UHFFFAOYSA-N
Pubchem ID :24729567

Safety of [ 918515-16-9 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H317-H319-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 918515-16-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 12
Num. arom. heavy atoms 9
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 46.49
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

45.75 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.27
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.4
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.03
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.94
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.78
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.68

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.33
Solubility 0.843 mg/ml ; 0.00467 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.96
Solubility 1.96 mg/ml ; 0.0108 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.47
Solubility 0.0606 mg/ml ; 0.000336 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.41 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.35

Application In Synthesis of [ 918515-16-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 918515-16-9 ]

[ 918515-16-9 ] Synthesis Path-Downstream   1~1

  • 1
  • [ 1000340-39-5 ]
  • [ 68-12-2 ]
  • [ 918515-16-9 ]
YieldReaction ConditionsOperation in experiment
52% Step 2: A solution of C38 (8 g, 34.632 mM) in THF (160 mL) was cooled to -780C, treated with n-BuLi (1.6M, 5OmL, 79.63 mM), and stirred for 30 min. at -780C. The cold solution was then slowly treated with DMF (5.056 g, 69.264m M). The reaction mixture was allowed to warm to 25C, stirred for 2 hr., and treated with water (2 mL) to quench the reaction. The reaction mixture was concentrated under reduced pressure and treated with saturated aq. NH4CI (28 mL), and the solids were collected and dried under reduced pressure. The resultant pale yellow solid (3.5g, 52%) was then purified using silica gel column to provide 4-chloro-1 H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (C39). 1HNMR(CDCI3) 8: 12.6-12.8 (b,1 H),10.4-10.6 (s,1 H),8.26-8.3 (d,1 H),8.12-8.18 (s,1 H),7.26-7.3 (d,1 H). Mass:(M+1 ) 181 calculated for mol. form. C8H5CIN2O.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 918515-16-9 ]

Chlorides

Chemical Structure| 688782-02-7

A161051 [688782-02-7]

4-Chloro-3-methyl-1H-pyrrolo[2,3-b]pyridine

Similarity: 0.90

Chemical Structure| 920965-87-3

A319795 [920965-87-3]

4-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile

Similarity: 0.85

Chemical Structure| 55052-28-3

A142462 [55052-28-3]

4-Chloro-7-azaindole

Similarity: 0.83

Chemical Structure| 920966-03-6

A140337 [920966-03-6]

4-Chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid

Similarity: 0.80

Chemical Structure| 346599-62-0

A319783 [346599-62-0]

4-Chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one

Similarity: 0.78

Aldehydes

Chemical Structure| 171919-36-1

A195917 [171919-36-1]

1-Methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde

Similarity: 0.81

Chemical Structure| 728034-12-6

A188666 [728034-12-6]

1H-Pyrrolo[2,3-b]pyridine-4-carbaldehyde

Similarity: 0.75

Chemical Structure| 757978-33-9

A210999 [757978-33-9]

5-Bromo-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde

Similarity: 0.74

Chemical Structure| 900514-07-0

A194920 [900514-07-0]

3-Iodo-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde

Similarity: 0.72

Chemical Structure| 876-72-2

A107815 [876-72-2]

4-Chloro-1H-indole-3-carbaldehyde

Similarity: 0.66

Related Parent Nucleus of
[ 918515-16-9 ]

Other Aromatic Heterocycles

Chemical Structure| 688782-02-7

A161051 [688782-02-7]

4-Chloro-3-methyl-1H-pyrrolo[2,3-b]pyridine

Similarity: 0.90

Chemical Structure| 920965-87-3

A319795 [920965-87-3]

4-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile

Similarity: 0.85

Chemical Structure| 55052-28-3

A142462 [55052-28-3]

4-Chloro-7-azaindole

Similarity: 0.83

Chemical Structure| 171919-36-1

A195917 [171919-36-1]

1-Methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde

Similarity: 0.81

Chemical Structure| 920966-03-6

A140337 [920966-03-6]

4-Chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid

Similarity: 0.80